Functional imaging techniques for evaluation of sarcomas

Cancer Imaging

Volumn 5, Issue 1, 2005, Pages 58-65

  Hicks, Rodney J ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Bone scintigraphy; FDG; In 111 octreotide; PET; Tl 201

Indexed keywords

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SARCOMA;

DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; SARCOMA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33645256062     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2005.0007     Document Type: Article

References (44)

1. Siegel MJ. Magnetic resonance imaging of musculoskeletal soft tissue masses. Radiol Clin North Am 2001; 39: 701-20.
2. Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin 2004; 54: 94-109.
3. Keeling DH. Adverse reactions and untoward events associated with the use of radiopharmaceuticals. In: Textbook of radio-pharmacy: theory and practice, 2nd edn. Sampson CB, ed. Switzerland: Gordon and Breach Scientific Publishers, 1994: 285-98.
4. Hicks RJ. Nuclear medicine techniques provide unique physiologic characterization of suspected and known soft tissue and bone sarcomas. Acta Orthop Scand 1997; 273: 25-36.
5. Miles KA. Measurement of tissue perfusion by dynamic computed tomography. Br J Radiol 1991; 64: 409-12.
6. Tacikowska M. Dynamic magnetic resonance imaging in soft tissue tumors-assessment of the diagnostic value of tumor enhancement rate indices. Med Sci Monit 2002; 8: MT53-7.
7. Negendank WG. MR spectroscopy of musculoskeletal soft-tissue tumors. Magn Reson Imaging Clin N Am 1995; 3: 713-25.
8. Caluser CI, Abdel-Dayem HM, Macapinlac HA et al. The value of thallium and three-phase bone scans in evaluation of bone and soft tissue sarcomas. Eur J Nucl Med 1994; 21: 1198-205.
9. Schwarzbach M, Willeke F, Dimitrakopoulou-Strauss A et al. Functional imaging and detection of local recurrence in soft tissue sarcomas by positron emission tomography. Anticancer Res 1999; 19: 1343-9.
10. 201Tl uptake in tumours. Eur J Nucl Med 1989; 15: 376-9.
11. Cox PH, Belfer AJ, van der Pompe WB. Thallium-201 chloride uptake in tumors, a possible implication in heart scintigraphy. Br J Radiol 1976; 49: 767-8.
12. Ramanna L, Waxman A, Binney G, Waxman S, Mirra J, Rosen G. Thallium-201 scintigraphy in bone sarcoma: comparison with gallium-67 and technetium-MDP in the evaluation of chemotherapeutic response. J Nucl Med 1990; 31: 567-72.
13. Ohtomo K, Terui S, Yokoyama R et al. Thallium-201 scintig-raphy to assess effect of chemotherapy in osteosarcoma. J Nucl Med 1996; 37: 1444-8.
14. Colarinha P, Fonseca AT, Salgado L, Vierira MR. Diagnosis of malignant change in Paget's disease by Tl-201. Clin Nucl Med 1996; 21: 299-301.
15. 99m-tetrofosmin as a substrate for p-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells. J Nucl Med 1996; 37: 1578-82.
16. 99m-MIBI uptake in benign and malignant bone lesions: a comparative study. J Nucl Med 1992; 33: 319-24.
17. 99m-MIBI and thallium-201 in tumor cell lines. J Nucl Med 1996; 37: 1551-6.
18. 99mTc-MIBI scintigraphy in the evaluation of the response of osteosarcoma to chemotherapy. Eur J Nucl Med 1997; 24: 511-5.
19. 99m-MIBI scintigraphy. J Nucl Med 1997; 38: 501-6.
20. 99mTc-MIBI scintigraphy in musculoskeletal tumors. J Nucl Med 2001; 42: 33-7.
21. 99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. J Nucl Med 1996; 37: 1476-9.
22. Leskinen-Kallio S. Positron emission tomography in oncology. Clin Physiol 1994; 14: 329-5.
23. Yamamoto T, Seino Y, Fukumoto H et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990; 170: 223-30.
24. Okada J, Yoshikawa K, Itami M et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992; 33: 325-9.
25. Bastiaannet E, Groen H, Jager PL et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 2004; 30: 83-101.
26. Kole AC, Nieweg OE, Hoekstra HJ, van Horn JR, Koops HS, Vaalburg W. Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors. J Nucl Med 1998; 39: 810-5.
27. 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26: 22-30.
28. Nieweg OE, Pruim J, van Ginkel RJ et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996; 37: 257-61.
29. 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med 2001; 42: 713-20.
30. Eary JF, Mankoff DA. Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med 1998; 39: 250-4.
31. Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Active and passive mechanisms of [fluorine-18] fluorodeoxyglu- cose uptake by proliferating and prenecrotic cancer cells in vivo: a microautoradiographic study. JNucl Med 1994; 35: 1067-75.
32. Koh WJ, Rasay JS, Evans ML et al. Imaging tumor hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22: 199-212.
33. Kubota K, Yamada S, Ishiwata K et al. Evaluation of the treatment response of lung cancer with positron emission tomography and L-[methyl- C]methionine: a preliminary study. Eur J Nucl Med 1993; 20: 495-501.
34. Kole AC, Plaat BE, Hoekstra HJ, Vaalburg W, Molenaar WM. FDG and L-[1-11C]-tyrosine imaging of soft-tissue tumors before and after therapy. JNucl Med 1999; 40: 381-6.
35. Wester HJ, Herz M, Weber W, Heiss P et al. Synthesis and radiopharmacology of O-(2-[F]fluoroethyl)-L-tyrosine for tumor imaging. JNucl Med 1999; 40: 205-12.
36. Shields AF, Grierson JR, Dohmen BM et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4: 1334-6.
37. Cobben DC, Elsinga PH, Suurmeijer AJ et al. Detection and grading of soft tissue sarcomas of the extremities with F-3'-fluoro-3'-deoxy-L-thymidine. Clin Cancer Res 2004; 10: 1685-90.
38. Kobayashi H, Kotoura Y, Hosono M et al. Diagnostic value of Tc- (V) DMSA for chondrogenic tumours with positive TcHMDP uptake on bone scintigraphy. Clin Nucl Med 1995; 20: 361-4.
39. Kobayashi H, Sakahara H, Itoh T et al. Technetium-99m (V)dimercaptosuccinic acid uptake in intra-abdominal massive deposit of amyloid protein. J Nucl Med 1993; 34: 815-7.
40. Kobayashi H, Sakahara H, Hosono M et al. Soft-tissue tumors: diagnosis with Tc- (V) dimercaptosuccinic acid scintigraphy. Radiology 1994; 190: 277-80.
41. Abe H, Terui S, Terauchi T et al. Comparison of Tc- pertechnetate with Tl-201 and Ga-67 scintigraphy of malignant soft-tissue tumors. Clin Nucl Med 1997; 22: 38-41.
42. Cheung NK, Canete A, Cheung IY, Ye JN, Liu C. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. Int J Cancer 1993; 54: 499-505.
43. Ferrari S, Dondi M, Fanti S et al. Somatostatin receptor (SSTR) scintigraphy in patients with osteosarcoma. Cancer Biother Radiopharm 2003; 18: 847-51.
44. Bhaumik S, Walls Z, Puttaraju M, Mitchell LG, Gambhir SS. Molecular imaging of gene expression in living subjects by spliceosome-mediated RNA trans-splicing. Proc Natl Acad Sci USA 2004; 101: 8693-8.